Peptide therapeutics for healing, metabolic health, recovery and wellness have entered a new chapter in Arkansas.
Following the Food and Drug Administration’s Pharmacy Compounding Advisory Committee meetings July 23-24, the panel recommended six peptides for inclusion on the Section 503A Bulk Drug Substances List, clearing a key advisory hurdle toward regulated compounding.
The committee voted in favor of BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. EmideltidHe, also known as DSIP, was not recommended. The recommendations are advisory and nonbinding; the FDA must still complete formal notice-and-comment rulemaking before the peptides can be legally compounded by 503A pharmacies. The process typically takes months.
Demand in Arkansas has been strong. Dr. Missy Clifton, a triple board-certified dermatologist specializing in laser surgery and antiaging and regenerative medicine at Premier Dermatology, said patients at her northwest Arkansas clinics frequently request BPC-157, TB-500, GHK-Cu, retatrutide, ipamorelin and tesamorelin for weight management and muscle support. Requests also include Thymosin Alpha-1 and LL-37 for immune support, Selank for anxiety, and SEMAX for mental clarity.
Dr. Jeanne Wei, chair of the Donald W. Reynolds Department of Geriatrics at the University of Arkansas for Medical Sciences and executive director of the Reynolds Institute on Aging, said interest tends to be stronger among younger patients while remaining more measured in geriatric populations focused on longevity…